Astellas Pharma China, Inc.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary
- Established
- 1994-10-14
- Employees
- -
- Market Cap
- -
- Website
- https://www.astellas.com.cn
An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Phase 3
Active, not recruiting
- Conditions
- Metastatic Hormone Sensitive Prostate Cancer
- Interventions
- First Posted Date
- 2019-09-03
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 180
- Registration Number
- NCT04076059
- Locations
- 🇨🇳
Site CN86027, Shanghai, China
🇨🇳Site CN86020, Shenyang, China
🇨🇳Site CN86022, Beijing, China
A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- First Posted Date
- 2018-09-06
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 385
- Registration Number
- NCT03660059
- Locations
- 🇨🇳
Site CN00061, Changchun, China
🇨🇳Site CN00072, Guangzhou, China
🇰🇷Site KR00035, Seoul, Korea, Republic of
Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients
Phase 4
Completed
- Conditions
- Kidney Transplant
- Interventions
- Drug: Induction therapyDrug: Mycophenolic acid drugsDrug: Corticosteroids
- First Posted Date
- 2018-08-23
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 284
- Registration Number
- NCT03644485
- Locations
- 🇨🇳
Site CN08619, Beijing, China
🇨🇳Site CN08609, Changsha, China
🇨🇳Site CN08603, Tianjin, China
Efficacy and Safety Study of the Switch From Cyclosporin to Tacrolimus in Renal Transplant Recipients
Phase 4
Completed
- Conditions
- Renal Transplant Recipients
- Interventions
- First Posted Date
- 2016-03-11
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT02706678
A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections
- First Posted Date
- 2016-02-10
- Last Posted Date
- 2016-02-10
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 2555
- Registration Number
- NCT02678598
Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT02646800
Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT02646774
A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis
Phase 3
Completed
- Conditions
- Lupus Nephritis
- Interventions
- First Posted Date
- 2015-05-29
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 314
- Registration Number
- NCT02457221
- Locations
- 🇨🇳
Site CN00005, Dalian, Liaoning, China
🇨🇳Site CN00045, Liuzhou, Guangxi, China
🇨🇳Site CN00025, Nanjing, Jiangsu, China
Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients
Completed
- Conditions
- Kidney Transplant Recipients
- Interventions
- Drug: ATF-Fresenius S
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 950
- Registration Number
- NCT02392312
- Locations
- 🇨🇳
Site: CN00017, Jinan, China
🇨🇳Site: CN00023, Guangzhou, China
🇨🇳Site: CN00033, Yantai, China
A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule
- First Posted Date
- 2014-10-20
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT02268201
© Copyright 2025. All Rights Reserved by MedPath